Neuroscience · asia
Before Proteins Clump: ALS Research Identifies a New Pathway for Neurons to Clear Abnormal TDP-43
A Nagoya University team has found that neurons can use TBK1 and interferon beta signaling to activate immunoproteasomes that break down aggregation-prone TDP-43. Evidence from cells, animals, and patient tissue points to a new direction for therapeutic research, but the pathway has not yet been shown to slow ALS progression.
One important question in research on amyotrophic lateral sclerosis (ALS) is whether neurons can clear abnormal proteins before they clump together. A team from Nagoya University, King’s College London in the UK, and other institutions has now identified an intracellular defense pathway that may help explain how neurons handle aggregation-prone TDP-43 and why this defense fails in disease.
The study was published in EMBO Reports on October 5, and Nagoya University released a research announcement in October. TDP-43 normally participates in RNA regulation in the cell nucleus; in most ALS cases, however, it appears in the cytoplasm and forms abnormal aggregates. The team focused on “monomeric” TDP-43 that has not yet formed aggregates but is prone to aggregation, shifting attention to the stage before proteins clump together.
Experiments showed that this form of TDP-43 can directly interact with the enzyme TBK1 and promote its activation, which then induces interferon beta (IFNβ) signaling and increases immunoproteasome production in neurons. The immunoproteasome is a protein-degrading complex usually associated with immune responses; here, it helps neurons clear aggregation-prone TDP-43. The researchers also observed this mechanism in lower motor neurons differentiated from human induced pluripotent stem cells.
The finding fills in a piece of the puzzle surrounding TBK1 function. TBK1 was already known to be involved in autophagy, the process by which cells enclose material destined for clearance and deliver it for degradation. Under the conditions of these experiments, however, the team found that blocking the relevant degradation pathways did not prevent TBK1 from promoting TDP-43 clearance. The results indicate that neurons can also use a protein-processing route that does not depend on autophagy.
Disease-related evidence suggests that this pathway may be disrupted at more than one point. According to the university’s Japanese-language announcement, TBK1 mutants from ALS patients could not induce IFNβ normally. Analysis of patient spinal cord tissue also found reduced IFNβ receptor expression in motor neurons with TDP-43 pathology. These findings support the possibility of impaired defense signaling, but are not sufficient to establish the full causal sequence in patients.
Animal experiments provided another layer of support: in ALS model mice carrying the SOD1-G93A mutation, deleting one copy of the Tbk1 gene weakened immunoproteasome induction and increased the accumulation of proteins bearing multiple ubiquitin tags in the spinal cord. This result indicates that TBK1 is involved in protein clearance in vivo, but cannot be directly interpreted as evidence that activating this pathway can already clear TDP-43 aggregates in patients or improve motor function.
Next, the team plans to look for other compounds that can activate immunoproteasomes in motor neurons. However, whether this mechanism is protective throughout the course of ALS and frontotemporal dementia remains unclear. Data on the expression of IFNβ and immunoproteasome subunits in patient tissue also remain incomplete. Moving from identifying a clearance pathway to developing a treatment will require answers to questions such as when to intervene, how to modulate the pathway safely, and whether it can actually preserve neuronal function.